English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Osamu Hotta, MD, Department of Nephrology, Sendai Shakaihoken Hospital, 3-16-1 Tsutsumimachi, Aoba-ku, Sendai, Miyagi, 981 (Japan) Dear Sir, The endothelial leukocyte adhesion molecule (ELAM)-1 ‚ a member of the selectin family with a lectin-like N-terminal domain [1], binds granulocytes, monocytes and a subset of memory T cells [2-4]. ELAM-1 is expressed only on vascular endothelium, predominantly on postcapillary venules [5-7]. Expression of ELAM-1 on vascular endothelium can be observed in the proximity of cells producing inflammatory cytokines such as interleukin-1 and the tumor necrosis factor, stimuli which, in vitro, are known to induce an upregulation of adhesion [5]. Recently, a quantitative sandwich ELISA for ELAM-1 in the fluid phase (soluble ELAM-1, sELAM-1) has been developed [6]. The expression of ELAM-1 has been described only on activated endothelial cells, not on other cell types; therefore, levels of ELAM-1 in serum may provide a basis for the assessment of endothelial damage or activation [6, 7]. We examined the level of s-ELAM-1 in patients with IgA nephropathy (IgAN), and those with polycystic kidney disease (PCK), paying special attention to its correlation with the decline of renal function. A total of 38 patients were enrolled in the present study: 24 with IgAN, and 14 with PCK with varying degrees of renal function. Twenty-seven healthy adult volunteers served as normal controls for s-ELAM-1 assay. They were determined healthy by biochemical tests and urinalysis. All blood samples were obtained in the morning (07.00-09.00) at Sendai Shakaihoken Hospital. In 5 patients with IgAN, blood samples were obtained twice: before steroid therapy and 1

Soluble ELAM-1 Is Elevated with the Progression of IgA Nephropathy but Not with That of Polycystic Kidney Disease